COMT and Alpha-Tocopherol Effects in Cancer Prevention: Gene-Supplement Interactions in Two Randomized Clinical Trials.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
01 07 2019
01 07 2019
Historique:
received:
28
05
2018
revised:
06
08
2018
accepted:
29
10
2018
pubmed:
10
1
2019
medline:
9
7
2020
entrez:
10
1
2019
Statut:
ppublish
Résumé
Vitamins are among the most frequently used supplements (48% of US adults). However, little is known about contributions of genetic variation to their efficacy and safety. Multiple pathways link catechol-O-methyltransferase (COMT) to the vitamin E supplement, alpha-tocopherol, and cancer. Here we determined if COMT exerted pharmacogenetic effects on cancer prevention in two randomized trials of alpha-tocopherol supplementation. Pharmacogenetic effects of common COMT rs4680 (val158met), which encodes a nonsynonymous valine-to-methionine substitution, were examined in the trial plus a 10-year post-trial follow-up (overall) period of The Women's Genome Health Study (WGHS, N = 23 294), a 10-year alpha-tocopherol and aspirin trial with 10 years post-trial follow-up. Results were validated in a case/control (N = 2396/2235) subset of the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study (ATBC, N = 29 133). The primary outcome was total cancers. Rates of cancer types prevalent in women (colorectal, breast, lung, uterine, and lymphoma/leukemia) were also examined. All statistical tests were two-sided. Random-effects meta-analysis of rs4680 genotype strata, in WGHS and ATBC overall periods, revealed differential alpha-tocopherol effects compared with placebo: met/met (hazard ratio [HR] = 0.88; 95% confidence interval [CI] = 0.80 to 0.97; P = .01), val/met (HR = 0.99; 95% CI = 0.92 to 1.06; P = .74), and val/val (HR = 1.18; 95% CI = 1.06 to 1.31; P = .002) with a statistically significant COMT by alpha-tocopherol interaction (Pinteraction <.001). Timing of effects differed, with stronger effects in WGHS trial and ATBC post-trial. Pharmacogenetic analysis of COMT and cancer prevention in two large randomized trials revealed statistically significant COMT by alpha-tocopherol interaction, such that alpha-tocopherol was beneficial among rs4680 met-allele (28.0%), but not val-allele (22.8%) homozygotes. These effects indicate the need for additional studies of genetic variation as a determinant of the benefits and possible harms of over-the-counter supplements, like alpha-tocopherol, used for health promotion.
Sections du résumé
BACKGROUND
Vitamins are among the most frequently used supplements (48% of US adults). However, little is known about contributions of genetic variation to their efficacy and safety. Multiple pathways link catechol-O-methyltransferase (COMT) to the vitamin E supplement, alpha-tocopherol, and cancer.
METHODS
Here we determined if COMT exerted pharmacogenetic effects on cancer prevention in two randomized trials of alpha-tocopherol supplementation. Pharmacogenetic effects of common COMT rs4680 (val158met), which encodes a nonsynonymous valine-to-methionine substitution, were examined in the trial plus a 10-year post-trial follow-up (overall) period of The Women's Genome Health Study (WGHS, N = 23 294), a 10-year alpha-tocopherol and aspirin trial with 10 years post-trial follow-up. Results were validated in a case/control (N = 2396/2235) subset of the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study (ATBC, N = 29 133). The primary outcome was total cancers. Rates of cancer types prevalent in women (colorectal, breast, lung, uterine, and lymphoma/leukemia) were also examined. All statistical tests were two-sided.
RESULTS
Random-effects meta-analysis of rs4680 genotype strata, in WGHS and ATBC overall periods, revealed differential alpha-tocopherol effects compared with placebo: met/met (hazard ratio [HR] = 0.88; 95% confidence interval [CI] = 0.80 to 0.97; P = .01), val/met (HR = 0.99; 95% CI = 0.92 to 1.06; P = .74), and val/val (HR = 1.18; 95% CI = 1.06 to 1.31; P = .002) with a statistically significant COMT by alpha-tocopherol interaction (Pinteraction <.001). Timing of effects differed, with stronger effects in WGHS trial and ATBC post-trial.
CONCLUSION
Pharmacogenetic analysis of COMT and cancer prevention in two large randomized trials revealed statistically significant COMT by alpha-tocopherol interaction, such that alpha-tocopherol was beneficial among rs4680 met-allele (28.0%), but not val-allele (22.8%) homozygotes. These effects indicate the need for additional studies of genetic variation as a determinant of the benefits and possible harms of over-the-counter supplements, like alpha-tocopherol, used for health promotion.
Identifiants
pubmed: 30624689
pii: 5260812
doi: 10.1093/jnci/djy204
pmc: PMC6624170
doi:
Substances chimiques
beta Carotene
01YAE03M7J
COMT protein, human
EC 2.1.1.6
Catechol O-Methyltransferase
EC 2.1.1.6
alpha-Tocopherol
H4N855PNZ1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
684-694Subventions
Organisme : NHLBI NIH HHS
ID : K01 HL130625
Pays : United States
Organisme : NCCIH NIH HHS
ID : K24 AT009282
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA182913
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201500005C
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Science. 2006 Dec 22;314(5807):1930-3
pubmed: 17185601
Clin Chem. 2008 Feb;54(2):249-55
pubmed: 18070814
Mol Biol Rep. 2013 Feb;40(2):1835-41
pubmed: 23096092
J Pain. 2010 Sep;11(9):910-5, 915.e1-9
pubmed: 20627703
Ann Epidemiol. 1994 Jan;4(1):1-10
pubmed: 8205268
Am J Clin Nutr. 1995 Dec;62(6 Suppl):1427S-1430S
pubmed: 7495243
Ann Intern Med. 2013 Jul 16;159(2):77-85
pubmed: 23856681
Neuropsychopharmacology. 2008 Dec;33(13):3037-45
pubmed: 17805313
Nature. 1979 Apr 19;278(5706):737-8
pubmed: 431730
Nature. 2011 Aug 31;477(7362):54-60
pubmed: 21886157
Oncotarget. 2017 Mar 28;8(13):20925-20938
pubmed: 28178648
Anticancer Res. 2010 Jan;30(1):217-20
pubmed: 20150638
Tumour Biol. 2014 Mar;35(3):2343-50
pubmed: 24146281
Cancer Res. 2001 Sep 15;61(18):6716-22
pubmed: 11559542
Nat Genet. 2014 Jun;46(6):543-550
pubmed: 24816252
Br J Cancer. 2001 Sep 14;85(6):859-62
pubmed: 11556837
Int J Environ Health Res. 2014;24(3):256-68
pubmed: 23869875
Drug Metab Rev. 2017 Feb;49(1):56-83
pubmed: 27826992
N Engl J Med. ;377(8):793-5
pubmed: 28836424
Pharmacogenet Genomics. 2005 Aug;15(8):535-46
pubmed: 16006997
Pharmacogenet Genomics. 2012 Oct;22(10):716-24
pubmed: 22890010
Ann N Y Acad Sci. 1987;498:186-99
pubmed: 3304060
Pharmacogenomics J. 2016 Oct;16(5):454-60
pubmed: 27457818
Pharmacogenetics. 1996 Jun;6(3):243-50
pubmed: 8807664
Ann Intern Med. 2013 Dec 17;159(12):824-34
pubmed: 24217421
Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):2160-7
pubmed: 25035343
Menopause. 2014 Apr;21(4):415-20
pubmed: 23880798
JAMA. 2005 Jul 6;294(1):56-65
pubmed: 15998891
N Engl J Med. 2005 Mar 31;352(13):1293-304
pubmed: 15753114
N Engl J Med. 2017 May 25;376(21):2090-2091
pubmed: 28538113
Am J Hum Genet. 2004 Nov;75(5):807-21
pubmed: 15457404
Am J Hum Genet. 2005 May;76(5):887-93
pubmed: 15789306
N Engl J Med. 1994 Apr 14;330(15):1029-35
pubmed: 8127329
J Biol Chem. 1958 Sep;233(3):702-5
pubmed: 13575440
Recent Pat Biotechnol. 2014;8(2):144-51
pubmed: 25185982
Sci Transl Med. 2014 Jan 29;6(221):221ra15
pubmed: 24477002
J Natl Cancer Inst. 1999 Dec 15;91(24):2102-6
pubmed: 10601381
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
Clin Lung Cancer. 2013 Jan;14(1):45-9
pubmed: 22658813
Pharmacogenomics J. 2016 Oct;16(5):430-8
pubmed: 27241058
Nat Genet. 2015 Nov;47(11):1294-1303
pubmed: 26414677
Am J Med Genet A. 2018 Oct;176(10):2121-2127
pubmed: 28940864
Cancer Res. 2008 Jul 15;68(14):5997-6005
pubmed: 18632656
JAMA. 2016 Oct 11;316(14):1464-1474
pubmed: 27727382
Pharmacogn Rev. 2010 Jul;4(8):118-26
pubmed: 22228951